Patients With DLBCL at Elevated Risk of Non-cancer-related Death

Share this content:
Patients with DLBCL were at an increased risk of non-cancer-related deaths from blood disease, infection, gastrointestinal disease, vascular diseases, and lung disease.
Patients with DLBCL were at an increased risk of non-cancer-related deaths from blood disease, infection, gastrointestinal disease, vascular diseases, and lung disease.

Patients with diffuse large B cell lymphoma (DLBCL) are at an elevated mortality risk from non-cancer causes even after the disease is cured, according to a study published in Cancer.1

The incorporation of rituximab into standard treatment regimens for DLBCL has improved long-term survival and cure rates. Patients are, however, at risk of death from factors other than this malignancy, including treatment-related side effects and disease-induced immunosuppression.

For this study, researchers evaluated data from the US Surveillance, Epidemiology, and End Results (SEER) program to determine cancer-specific and non-cancer-related mortality rates among patients diagnosed after the introduction of rituximab in 2002.

Risk profiles were developed using clinical and demographic data; patients were grouped into low-, medium-, and high-risk groups. Standardized mortality ratios (SMRs) were used to compare mortality rates among patients with those of the general population.

The 18,047 patients included were divided into 1 of the 3 risk tertiles based on age, disease stage at diagnosis, ethnicity, gender, and sociodemographic data. The strongest independent risk factors were age and disease stage at diagnosis.

Patients in the low-, medium-, and high-risk groups had cure proportions of 73%, 49%, and 27%, respectively, though the authors noted some uncertainty in these figures.

RELATED: Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL

Patients with DLBCL were also at an increased risk of non-cancer-related deaths from blood disease, infection, gastrointestinal disease, vascular diseases, and lung disease. SMRs in between 0 and 59 months post-diagnosis were particularly high; after 59 months these risks were lower, though not non-existent.

The highest SMR was for blood disease in between 0 and 59 months post-diagnosis.

The authors concluded that even after the introduction of rituximab, patients diagnosed with DLBCL are at an elevated risk of death from non-cancer causes. They also noted that DLBCL-specific mortality is still a risk for patients even after 2-year survival is reached.

Reference

  1. Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017 May 2. doi: 10.1002/cncr.30739 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters